Total Payments
$937,123
2024 Payments
$125,952
Companies
70
Transactions
1,372
Medicare Patients
5,688
Medicare Billing
$671,757
Payment Breakdown by Category
Other$436,637 (46.6%)
Consulting$352,159 (37.6%)
Research$102,962 (11.0%)
Food & Beverage$32,126 (3.4%)
Travel$11,806 (1.3%)
Education$1,433 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $352,159 | 134 | 37.6% |
| Honoraria | $175,112 | 23 | 18.7% |
| Grant | $164,750 | 14 | 17.6% |
| Unspecified | $102,962 | 40 | 11.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,490 | 36 | 9.3% |
| Food and Beverage | $32,126 | 1,037 | 3.4% |
| Travel and Lodging | $11,806 | 39 | 1.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,545 | 4 | 0.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,740 | 1 | 0.2% |
| Education | $1,433 | 44 | 0.2% |
Payments by Type
General
$834,161
1,332 transactions
Research
$102,962
34 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $205,287 | 221 | $0 (2024) |
| Allergan, Inc. | $132,847 | 91 | $0 (2022) |
| Sensus Healthcare, Inc. | $100,502 | 5 | $0 (2019) |
| Bausch Health US, LLC | $69,665 | 12 | $0 (2021) |
| Solta Medical, a division of Bausch Health US, LLC | $69,484 | 30 | $0 (2024) |
| Aqua Pharmaceuticals | $65,935 | 42 | $0 (2017) |
| Merz North America, Inc. | $51,704 | 63 | $0 (2023) |
| Galderma Laboratories, L.P. | $39,621 | 44 | $0 (2024) |
| Almirall LLC | $21,404 | 38 | $0 (2022) |
| Musculoskeletal Transplant Foundation Inc. | $17,827 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $125,952 | 192 | ABBVIE INC. ($78,614) |
| 2023 | $92,846 | 162 | ABBVIE INC. ($70,259) |
| 2022 | $142,747 | 187 | ABBVIE INC. ($51,763) |
| 2021 | $73,507 | 146 | Allergan, Inc. ($22,709) |
| 2020 | $45,649 | 141 | Allergan, Inc. ($14,150) |
| 2019 | $122,480 | 180 | Allergan Inc. ($37,861) |
| 2018 | $130,680 | 160 | Bausch Health US, LLC ($40,175) |
| 2017 | $203,261 | 204 | Aqua Pharmaceuticals ($65,935) |
All Payment Transactions
1,372 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $44.05 | General |
| 12/12/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Dermatology | ||||||
| 12/12/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $7.20 | General |
| Category: Inflammation & Immunology | ||||||
| 12/12/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $5.99 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $34.27 | General |
| Category: Virology & Specialty Care | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $11.12 | General |
| Category: Immunology | ||||||
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $18.27 | General |
| Category: Dermatology | ||||||
| 11/24/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $5.56 | General |
| Category: DERMATOLOGY | ||||||
| 11/22/2024 | IBSA Institut Biochimique SA | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: ANTIBIOTIC | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: Dermatology | ||||||
| 11/13/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $7.78 | General |
| Category: Dermatology | ||||||
| 11/11/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $6.91 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Dermatology | ||||||
| 11/01/2024 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $5.37 | General |
| Category: Dermatology | ||||||
| 10/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $30.59 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $1.68 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Dermatology | ||||||
| 10/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | Galderma Laboratories, L.P. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $67,425 | 9 |
| A PROSPECTIVE, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY OF SCULPTRA AESTHETIC IN IMMUNO-COMPETENT SUBJECTS STRATIFIED BY FITZPATRICK SKIN TYPE I-VI | Galderma Laboratories, L.P. | $19,560 | 2 |
| SRT Keloid Study | Sensus Healthcare, Inc. | $5,000 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $4,273 | 2 |
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | Biofrontera Inc. | $3,581 | 5 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | Endo Pharmaceuticals Inc. | $1,901 | 7 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ABBVIE INC. | $1,007 | 3 |
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT | Biofrontera Inc. | $62.89 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 1,321 | 5,676 | $550,522 | $163,548 |
| 2022 | 26 | 1,499 | 6,389 | $571,825 | $169,779 |
| 2021 | 28 | 1,574 | 7,362 | $646,911 | $193,705 |
| 2020 | 25 | 1,294 | 6,041 | $549,789 | $144,725 |
Total Patients
5,688
Total Services
25,468
Medicare Billing
$671,757
Procedure Codes
106
All Medicare Procedures & Services
106 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 164 | 1,365 | $136,500 | $32,590 | 23.9% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 73 | 305 | $50,325 | $16,099 | 32.0% |
| 11310 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 82 | 334 | $51,770 | $15,830 | 30.6% |
| 11300 | Shaving of skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 82 | 395 | $49,375 | $15,125 | 30.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 123 | $23,985 | $10,977 | 45.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 90 | 203 | $30,450 | $10,621 | 34.9% |
| 11311 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 41 | 154 | $30,030 | $9,876 | 32.9% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 66 | 180 | $18,000 | $6,013 | 33.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 83 | 151 | $12,080 | $5,870 | 48.6% |
| 11305 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.5 cm or less | Office | 2023 | 44 | 109 | $14,170 | $4,741 | 33.5% |
| 11601 | Removal of cancer skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 17 | 31 | $12,245 | $4,074 | 33.3% |
| 11641 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 16 | 29 | $12,470 | $4,054 | 32.5% |
| 11640 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 25 | 42 | $14,700 | $3,606 | 24.5% |
| 11306 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 28 | 60 | $10,500 | $3,405 | 32.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 80 | 340 | $13,600 | $3,200 | 23.5% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2023 | 31 | 64 | $8,000 | $2,895 | 36.2% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 16 | 36 | $7,200 | $2,649 | 36.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 44 | 59 | $17,700 | $2,539 | 14.3% |
| 11600 | Removal of cancer skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 13 | 25 | $8,500 | $2,224 | 26.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 16 | 24 | $7,200 | $1,806 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $4,200 | $1,640 | 39.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 21 | 37 | $5,550 | $1,352 | 24.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 118 | 1,025 | $6,150 | $801.46 | 13.0% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 17 | 17 | $2,380 | $790.51 | 33.2% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Office | 2023 | 12 | 13 | $910.00 | $288.99 | 31.8% |
About Dr. Michael Gold, M.D
Dr. Michael Gold, M.D is a Specialist healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073549176.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Gold, M.D has received a total of $937,123 in payments from pharmaceutical and medical device companies, with $125,952 received in 2024. These payments were reported across 1,372 transactions from 70 companies. The most common payment nature is "Consulting Fee" ($352,159).
As a Medicare-enrolled provider, Gold has provided services to 5,688 Medicare beneficiaries, totaling 25,468 services with total Medicare billing of $671,757. Data is available for 4 years (2020–2023), covering 106 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Nashville, TN
- Active Since 06/23/2006
- Last Updated 09/04/2013
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1073549176
Products in Payments
- SKYRIZI (Biological) $53,275
- BOTOX COSMETIC (Biological) $28,193
- BOTOX (Biological) $21,592
- XEOMIN (Biological) $18,409
- Clarify Medical (Device) $15,000
- QBREXZA (Drug) $12,985
- XTRAC (Device) $12,675
- Xeomin (Biological) $11,750
- EUCRISA (Drug) $9,088
- AKLIEF (Drug) $7,845
- ADBRY (Biological) $5,480
- M22 (Device) $5,000
- SEYSARA (Drug) $4,989
- WYNZORA (Drug) $4,800
- Ameluz (Drug) $4,766
- LITFULO (Drug) $3,853
- ZILXI (Drug) $3,698
- Seysara (Drug) $3,686
- TREMFYA (Drug) $3,368
- Winlevi (Drug) $3,283
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Nashville
Dr. Kimberly Vincent, M.d, M.D
Specialist — Payments: $1.5M
Specialist $1.5M
Dr. Brian Biesman, M.d, M.D
Specialist — Payments: $1.4M
Specialist $1.4M
Ms. Andrea Hayes, M.d, M.D
Specialist — Payments: $429,136
Specialist $429,136
Dr. Pat Whitworth, Md, MD
Specialist — Payments: $112,766
Specialist $112,766
Michael Stabile, M.d, M.D
Specialist — Payments: $43,099
Specialist $43,099
Dr. Thomas Davis, M.d, M.D
Specialist — Payments: $42,692
Specialist $42,692